Alpha Teknova reported second quarter 2026 total revenue of $12.2 million, an 18% increase from the prior year's $10.3 million, driven by growth in both Lab Essentials ($9.2 million) and Clinical Solutions ($2.4 million). The company raised its full-year 2026 revenue guidance to a range of $45-47 million and adjusted its Free Cash Outflow expectation downward to less than $8 million. Net loss narrowed to $3.2 million, or negative $0.06 per diluted share, compared to a net loss of $3.6 million in the same period last year. Gross margin improved to 40.1% from 38.7%, while operating expenses rose to $7.8 million due to increased sales and marketing headcount. The company launched its AI-powered Build-Tek custom order configurator and ended the quarter with $17.4 million in cash and short-term investments against $13.2 million in borrowings. Alpha Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics.